Research Insight
Mylan Launches First Generic of Nuvigil Tablets
Mylan N.V. announced the U.S. launch of Armodafinil Tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephalon's Nuvigil®. Mylan received final approval...
Research Insight
Allergan Announces Positive Pivotal Trial Results for Oculeve Intranasal...
Allergan plc announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary and secondary efficacy endpoints. With...
Research Insight
Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous...
Chugai Pharmaceutical Co Ltd announced that "Actemra® Subcutaneous Injection" (Actemra), the humanized antihuman IL-6 receptor monoclonal antibody, successfully met the primary endpoint in a dose...
Research Insight
Novartis announced Major study published in NEJM confirms Ultibro...
FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients ...
Research Insight
Phase III Trial of Regorafenib in Patients with Unresectable...
Bayer announced that a Phase III trial evaluating its oncology compound regorafenib (Stivarga®) for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met...
Research Insight
The use of Surgical Patch TachoSil (human thrombin/human fibrogen)...
Takeda Pharmaceutical Company Limited announced that the European Commission has granted an expanded indication for surgical patch TachoSil (human thrombin/human fibrogen) for use in adults...
Research Insight
Bristol-Myers Squibb’s Opdivo Receives Breakthrough Therapy Designation from US...
Designation based on results of Phase 3 study, CheckMate -141, in which Opdivo met its primary endpoint of overall survival, versus three standard of care...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.